OMO-1 in Solid Malignancies

NCT03138083 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped strategic reasons (not due to lack of efficacy or safety issues)

Conditions

Neoplasms

Interventions

DRUG: OMO-1

Sponsor

Octimet Oncology N.V.